Neoadjuvant chemoradiation therapy is beneficial for clinical stage T2 N0 esophageal cancer patients due to inaccurate preoperative staging
- PMID: 22269708
- PMCID: PMC4365971
- DOI: 10.1016/j.athoracsur.2011.10.061
Neoadjuvant chemoradiation therapy is beneficial for clinical stage T2 N0 esophageal cancer patients due to inaccurate preoperative staging
Abstract
Background: It remains unclear if patients with clinical stage T2 N0 (cT2 N0) esophageal cancer should be offered induction therapy vs surgical intervention alone.
Methods: This was a retrospective cohort study of cT2 N0 patients undergoing induction therapy, followed by surgical resection, or resection alone, at the Johns Hopkins Hospital from 1989 to 2009. Kaplan-Meier analysis was used to compare all-cause mortality in cT2 N0 patients who had resection alone vs those who had induction chemoradiation therapy, followed by resection.
Results: A study cohort of 69 patients was identified and divided into two groups: 55 patients (79.7%) received induction therapy and 14 (20.3%) did not. No statistically significant difference in 5-year survival rate was observed for the two groups: 49.5% for the resection-only group and 53.8% for the induction group. More than 50% of cT2 N0 patients were understaged.
Conclusions: For cT2 N0 esophageal cancer patients, the benefit of neoadjuvant therapy is still unclear. Induction therapy for cT2 N0 did not translate into a statistically significant improvement in survival. However, due to the significant understaging of T2 N0 patients, we recommend neoadjuvant therapy to all cT2N0 patients before operation.
Copyright © 2012 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
Figures


Comment in
-
Impact of neoadjuvant chemoradiation in early esophageal cancers.Ann Thorac Surg. 2012 Oct;94(4):1374-5. doi: 10.1016/j.athoracsur.2012.03.091. Ann Thorac Surg. 2012. PMID: 23006706 No abstract available.
Similar articles
-
Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients.J Surg Oncol. 2014 Mar;109(3):287-93. doi: 10.1002/jso.23498. Epub 2013 Nov 26. J Surg Oncol. 2014. PMID: 24277235
-
Clinical T2-T3N0M0 esophageal cancer: the risk of node positive disease.Ann Thorac Surg. 2011 Aug;92(2):491-6; discussion 496-8. doi: 10.1016/j.athoracsur.2011.04.004. Epub 2011 Jun 24. Ann Thorac Surg. 2011. PMID: 21704291
-
Treatment of clinical T2N0M0 esophageal cancer.Ann Surg Oncol. 2014 Nov;21(12):3739-43. doi: 10.1245/s10434-014-3929-6. Epub 2014 Jul 22. Ann Surg Oncol. 2014. PMID: 25047477
-
Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma.Ann Thorac Surg. 2004 Oct;78(4):1177-83. doi: 10.1016/j.athoracsur.2004.02.068. Ann Thorac Surg. 2004. PMID: 15464466 Review.
-
Neoadjuvant chemoradiation therapy in patients with surgically treated esophageal cancer.Acta Oncol. 2001;40(5):558-65. doi: 10.1080/028418601750444088. Acta Oncol. 2001. PMID: 11669326 Review.
Cited by
-
Predictors of Nodal Metastases for Clinical T2N0 Esophageal Adenocarcinoma.Ann Thorac Surg. 2018 Jul;106(1):172-177. doi: 10.1016/j.athoracsur.2018.02.087. Epub 2018 Apr 5. Ann Thorac Surg. 2018. PMID: 29627387 Free PMC article.
-
Evaluation of the reliability of clinical staging of T2 N0 esophageal cancer: a review of the Society of Thoracic Surgeons database.Ann Thorac Surg. 2013 Aug;96(2):382-90. doi: 10.1016/j.athoracsur.2013.03.093. Epub 2013 May 31. Ann Thorac Surg. 2013. PMID: 23731608 Free PMC article.
-
Interobserver variability in target volume delineation in definitive radiotherapy for thoracic esophageal cancer: a multi-center study from China.Radiat Oncol. 2021 Jun 9;16(1):102. doi: 10.1186/s13014-020-01691-4. Radiat Oncol. 2021. PMID: 34107984 Free PMC article.
-
Macrophage subtype predicts lymph node metastasis in oesophageal adenocarcinoma and promotes cancer cell invasion in vitro.Br J Cancer. 2015 Sep 1;113(5):738-46. doi: 10.1038/bjc.2015.292. Epub 2015 Aug 11. Br J Cancer. 2015. PMID: 26263481 Free PMC article.
-
Comparative Analysis of Blood and Bone Marrow for the Detection of Circulating and Disseminated Tumor Cells and Their Prognostic and Predictive Value in Esophageal Cancer Patients.J Clin Med. 2020 Aug 18;9(8):2674. doi: 10.3390/jcm9082674. J Clin Med. 2020. PMID: 32824841 Free PMC article.
References
-
- Rohatgi A, Naji S, Hamouda A, et al. Effect of understaging of early oesophageal cancers on treatment. J Clin Oncol. 2009;(27(suppl)) abstr el5572.
-
- Mariette C, Seitz F, Maillard E, et al. Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: analysis of a randomized controlled phase HI trial FFCD 9901. J Clin Oncol. 2010;28(15 suppl) abstr 4005. - PubMed
-
- Stiles B, Mirza F, Coppolino A, et al. Clinical T2-T3N0M0 esophageal cancer: the risk of node positive disease. Ann Thorac Surg. 2011;92:491–498. - PubMed
-
- Rice T, Mason D, Murthy S, et al. T2N0M0 esophageal cancer. J Thorac Cardiovasc Surg. 2007;133:317–324. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical